Kimberly Lynn Blackwell, MD

Professor of Medicine
Assistant Professor in Radiation Oncology
Member of the Duke Cancer Institute
Campus mail Duke Box 3893, Durham, NC 27710
Phone (919) 668-1748
Email address

Breast cancer angiogenesis
Breast cancer in younger women
Hormonal therapy
Neoadjurant therapy for breast cancer

Current Clinical Investigations

Principal Investigator, A Phase I-II Study of Neoadjuvant Evacet/Paclitaxel/Hyperthermia in Locally Advanced Breast Cancer Patients.

Investigator, Development of Screening Markers for Breast Cancer using Circulating Immune Complexes: Collaborative Study with Diagen Medical Technologies.

Principal Investigator, Use of Plasma D-Dimer as a Predictive Marker in Colorectal Carcinoma: Correlative Science Study with Genentech, Inc.

Principal Investigator, A randomized, Phase II study of gabapentin or glutamine to prevent the peripheral neuropathy/myalgia associated with weekly taxol administration in metastatic breast and lung cancer.

Investigator, A Phase 2, Randomized, Double-Masked, Multicenter Study of Two Dose Levels of ERA-923 for the treatment of Metastatic Breast Cancer in Postmenopausal Women who have failed Tamoxifen therapy. Genetics Institute.

Investigator, A Phase I Study of Combined Doxil/Hyperthermia in Stage IV Breast Cancer.

Education and Training

  • Fellow In Hematology Oncology, Medicine, Duke University, 1997 - 2000
  • Medical Resident, Medicine, Duke University, 1994 - 1997
  • M.D., Mayo School of Health Sciences, 1994


Kimmick, G, Edmond, SN, Bosworth, HB, Peppercorn, J, Marcom, PK, Blackwell, K, Keefe, FJ, and Shelby, RA. "Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy." Breast (Edinburgh, Scotland) 24, no. 5 (October 2015): 630-636.

Full Text

Blackwell, K, Semiglazov, V, Krasnozhon, D, Davidenko, I, Nelyubina, L, Nakov, R, Stiegler, G, Singh, P, Schwebig, A, Kramer, S, and Harbeck, N. "Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy." Annals of Oncology 26, no. 9 (September 2015): 1948-1953.

Full Text

Siamakpour-Reihani, S, Owzar, K, Jiang, C, Scarbrough, PM, Craciunescu, OI, Horton, JK, Dressman, HK, Blackwell, KL, and Dewhirst, MW. "Genomic profiling in locally advanced and inflammatory breast cancer and its link to DCE-MRI and overall survival." International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 31, no. 4 (June 2015): 386-395.

Full Text

Krop, IE, Lin, NU, Blackwell, K, Guardino, E, Huober, J, Lu, M, Miles, D, Samant, M, Welslau, M, and Diéras, V. "Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA." Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 26, no. 1 (January 2015): 113-119.

Full Text

Harnden, K, and Blackwell, K. "Routine use of zoledronic acid in early-stage breast cancer." JNCCN Journal of the National Comprehensive Cancer Network 13, no. 4 (2015): 480-486.


Burstein, HJ, Cirrincione, CT, Barry, WT, Chew, HK, Tolaney, SM, Lake, DE, Ma, C, Blackwell, KL, Winer, EP, and Hudis, CA. "Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance)." Journal of clinical oncology : official journal of the American Society of Clinical Oncology 32, no. 35 (December 2014): 3959-3966.

Full Text

Tripathy, D, Harnden, K, Blackwell, K, and Robson, M. "Next generation sequencing and tumor mutation profiling: are we ready for routine use in the oncology clinic?." BMC Medicine 12, no. 1 (December 2014).

Full Text

Cardoso, F, Costa, A, Norton, L, Senkus, E, Aapro, M, André, F, Barrios, CH, Bergh, J, Biganzoli, L, Blackwell, KL, Cardoso, MJ, Cufer, T, El Saghir, N, Fallowfield, L, Fenech, D, Francis, P, Gelmon, K, Giordano, SH, Gligorov, J, Goldhirsch, A, Harbeck, N, Houssami, N, Hudis, C, Kaufman, B, Krop, I, Kyriakides, S, Lin, UN, Mayer, M, Merjaver, SD, Nordström, EB, Pagani, O, Partridge, A, Penault-Llorca, F, Piccart, MJ, Rugo, H, Sledge, G, Thomssen, C, Van't Veer, L, Vorobiof, D, Vrieling, C, West, N, Xu, B, and Winer, E. "ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)." Breast (Edinburgh, Scotland) 23, no. 5 (October 2014): 489-502.

Full Text

Shelby, RA, Edmond, SN, Wren, AA, Keefe, FJ, Peppercorn, JM, Marcom, PK, Blackwell, KL, and Kimmick, GG. "Self-efficacy for coping with symptoms moderates the relationship between physical symptoms and well-being in breast cancer survivors taking adjuvant endocrine therapy." Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 22, no. 10 (October 2014): 2851-2859.

Full Text

Zagar, TM, Vujaskovic, Z, Formenti, S, Rugo, H, Muggia, F, O'Connor, B, Myerson, R, Stauffer, P, Hsu, IC, Diederich, C, Straube, W, Boss, MK, Boico, A, Craciunescu, O, Maccarini, P, Needham, D, Borys, N, Blackwell, KL, and Dewhirst, MW. "Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer." International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 30, no. 5 (August 2014): 285-294.

Full Text